Abstract 693P
Background
PD-1/PD-L1 monoclonal antibodies have revolutionised the landscape of cancer treatment. Nonetheless, some PD-L1+ patients do not respond to or become resistant to such therapy. The elevated expression of PD-L1 in tumours makes it an attractive target for ADC development, which could potentially alter the treatment for PD-1/PD-L1 inhibitor refractory/resistant (R/R) cancers.
Methods
HLX43 is a novel PD-L1-targeting ADC consisting of an engineered anti-PD-L1 humanised IgG1 antibody linked to a camptothecin-based toxin, with a drug to antibody ratio of 8. Our innovative linker-payload is activated preferentially in the tumour microenvironment, enabling its tumour-specific release of the toxin without needing internalisation of the ADC. Toxin release in PD-L1+ cancer cells is efficient and tumour-specific, minimizing damage to normal cells and reducing systemic toxicity from non-specific toxin release in periphery. HLX43 was examined in antigen binding, internalisation, and plasma stability assays; efficacy studies were performed in multiple CDX and PDX models.
Results
HLX43 has been shown to have similar affinity and internalisation rates as the parental antibody. It was stable in the plasma of rats and cynomolgus monkeys. In in vivo efficacy studies, HLX43 induced tumour regression in multiple PD-L+ CDX and PDX models, and was well tolerated across all dosing groups. Weekly administration of HLX43 8 mg/kg for three times significantly reduced tumours in the MDA-MB-231 model without causing weight loss. HLX43 exhibited superior anticancer efficacy compared to anti-PD-L1-GGFG-Dxd at equal doses in all models tested, including those with low PD-L1 levels, high heterogeneity, and non-responsiveness to PD-1/PD-L1 inhibitors. Preliminary toxicity assessments demonstrated good tolerability of HLX43 in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates. GLP toxicology studies will explore a higher dose at 20 mg/kg.
Conclusions
HLX43 showed promising efficacy and tolerability in preclinical assessments. It may offer a novel treatment for PD-1/PD-L1 inhibitor R/R cancers like NSCLC, HNSCC, ESCC, MEL, and OVC.
Clinical trial identification
Editorial acknowledgement
Shiqi Zhong of Shanghai Henlius Biotech, Inc.
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
Y. Shan, R. Liu, G. Song, H. Song, J. Jiang, C. Jia, Y. Chen, X. Yuan, Z. Hou, X. Wang, X. Hou, Y. Shen, C. Hu, H. Wei, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part-time Employment: Shanghai Henlius Biotech, Inc.
Resources from the same session
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
712TiP - A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Presenter: Angela Alistar
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17
719TiP - A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Presenter: Michele Moschetta
Session: Poster session 17